We have partnered with one Cambridges Premier Biomedical EIS Funds. Our clients have the opportunity to invest in a fund that focuses on therapeutic drug opportunities or technologies that enable drug discovery with an emphasis on Artificial Intelligence (AI).
The geographic scope shall be UK wide but will target the growing Cambridge biotech cluster which is now the global headquarters of AstraZeneca, and is home to many biotech companies some of which have subsequently been snapped up by large pharmaceutical companies.
Notable acquisitions from the Cambridge cluster include Astex (Otsuka), Convergence (Biogen IDEC), Heptares (EISAI), Kudos (AZ), Medimmune (AZ), Paradigm (Takeda) as well as IPO’s such as Abcam PLC, Abzena (Polytherics) PLC, Acacia Pharma PLC, GW Pharmaceuticals PLC and Horizon Discovery Group PLC. Over five years to 2018-19, the Cambridge Biotech Cluster grew four-fold to £4bn2.
The Human Health EIS fund is intended for investors who want to achieve capital growth (rather than income) by investing in a Portfolio of unquoted and/or AIM-listed companies, which have the potential to increase in value significantly. All the Investments we ordinarily make will be in EIS or SEIS qualifying companies.
We endeavour to take an active role in managing these Investments where possible to allow these potential companies to create value and achieve the best possible exits for our investors.
If you would like to receive a copy of the investment prospectus please fill out your contact details on the the below form and a copy with be delivered directly to your inbox. If you have any questions please feel free to call or email on the contacts below.